Camp4 Therapeutics Files 8-K
Ticker: CAMP · Form: 8-K · Filed: Oct 15, 2024 · CIK: 1736730
Sentiment: neutral
Topics: corporate-filing, financial-reporting
TL;DR
Camp4 Therapeutics filed an 8-K on 10/15/24 for corporate and financial updates.
AI Summary
Camp4 Therapeutics Corporation filed an 8-K on October 15, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements. The company, incorporated in Delaware, is located at One Kendall Square, Cambridge, MA.
Why It Matters
This filing indicates corporate updates and financial reporting for Camp4 Therapeutics, which could impact investors' understanding of the company's structure and financial health.
Risk Assessment
Risk Level: low — This is a routine corporate filing with no immediate indication of significant financial distress or major strategic shifts.
Key Numbers
- 001-42365 — SEC File Number (Identifies the company's filing with the SEC.)
- 81-1152476 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Camp4 Therapeutics Corporation (company) — Registrant
- October 15, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- One Kendall Square (location) — Principal executive offices address
- Cambridge, MA (location) — Principal executive offices city and state
FAQ
What specific amendments were made to Camp4 Therapeutics' articles of incorporation or bylaws?
The filing indicates amendments were made, but the specific details of these amendments are not provided in the provided text excerpt.
What type of financial statements are being reported?
The filing mentions 'Financial Statements and Exhibits' as an item information, but the specific type of financial statements (e.g., quarterly, annual) is not detailed in the excerpt.
When was Camp4 Therapeutics Corporation incorporated?
The filing states the state of incorporation is Delaware, but the exact date of incorporation is not provided in the excerpt.
What is the business phone number for Camp4 Therapeutics?
The business phone number listed for Camp4 Therapeutics is 617-651-8867.
What is the SIC code for Camp4 Therapeutics?
The Standard Industrial Classification (SIC) code for Camp4 Therapeutics is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 770 words · 3 min read · ~3 pages · Grade level 13.7 · Accepted 2024-10-15 16:06:36
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CAMP The Nasdaq Global Ma
Filing Documents
- tm2426167d1_8k.htm (8-K) — 30KB
- tm2426167d1_ex3-1.htm (EX-3.1) — 43KB
- tm2426167d1_ex3-2.htm (EX-3.2) — 75KB
- 0001104659-24-108583.txt ( ) — 353KB
- camp-20241015.xsd (EX-101.SCH) — 3KB
- camp-20241015_lab.xml (EX-101.LAB) — 33KB
- camp-20241015_pre.xml (EX-101.PRE) — 22KB
- tm2426167d1_8k_htm.xml (XML) — 4KB
03
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On October 15, 2024, in connection with the consummation of the initial public offering (the "IPO") of shares of common stock, par value $0.0001 per share ("Common Stock"), of CAMP4 Therapeutics Corporation (the "Company"), the Company filed a fifth amended and restated certificate of incorporation (the "Restated Certificate") with the Secretary of State of the State of Delaware, which became effective upon filing. The Company's board of directors and stockholders previously approved the Restated Certificate to be filed in connection with, and to be effective upon, the consummation of the IPO. The Restated Certificate amends and restates the Company's fourth amended and restated certificate of incorporation in its entirety to, among other things, (i) authorize 175 million shares of Common Stock, (ii) eliminate all references to previously existing series of preferred stock, (iii) authorize 25 million shares of undesignated preferred stock, par value $0.0001 per share, that may be issued from time to time, in one or more series, with the approval of the Company's board of directors and (iv) eliminate the ability of the Company's stockholders to take action by written consent in lieu of a meeting. The foregoing description of the Restated Certificate is qualified by reference to the Restated Certificate, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference. On October 15, 2024, in connection with the consummation of the IPO, the amended and restated bylaws of the Company (the "Amended and Restated Bylaws"), previously approved by the Company's board of directors and stockholders, became effective. The Amended and Restated Bylaws amend and restate the Company's bylaws in their entirety to, among other things, (i) establish procedures relating to the presentation of stockholder proposals at stockholder meetings, (ii) establish procedures relating
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Fifth Amended and Restated Certificate of Incorporation of CAMP4 Therapeutics Corporation. 3.2 Amended and Restated Bylaws of CAMP4 Therapeutics Corporation. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CAMP4 THERAPEUTICS CORPORATION By: /s/ Josh Mandel-Brehm Name: Josh Mandel-Brehm Title: President and Chief Executive Officer Date: October 15, 2024